113 related articles for article (PubMed ID: 28903354)
21. Prevention and Therapy of Metastatic HER-2
Ruzzi F; Palladini A; Clemmensen S; Strøbæk A; Buijs N; Domeyer T; Dorosz J; Soroka V; Grzadziela D; Rasmussen CJ; Nielsen IB; Soegaard M; Semprini MS; Scalambra L; Angelicola S; Landuzzi L; Lollini PL; Thorn M
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289916
[TBL] [Abstract][Full Text] [Related]
22. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
23. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
25. Mammary tumor formation and metastasis evoked by a HER2 splice variant.
Alajati A; Sausgruber N; Aceto N; Duss S; Sarret S; Voshol H; Bonenfant D; Bentires-Alj M
Cancer Res; 2013 Sep; 73(17):5320-7. PubMed ID: 23867476
[TBL] [Abstract][Full Text] [Related]
26. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
27. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic cell therapy for a murine mammary carcinoma.
Morecki S; Yacovlev E; Diab A; Slavin S
Cancer Res; 1998 Sep; 58(17):3891-5. PubMed ID: 9731499
[TBL] [Abstract][Full Text] [Related]
30. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
[TBL] [Abstract][Full Text] [Related]
31. Role of exon-16-deleted HER2 in breast carcinomas.
Castiglioni F; Tagliabue E; Campiglio M; Pupa SM; Balsari A; Ménard S
Endocr Relat Cancer; 2006 Mar; 13(1):221-32. PubMed ID: 16601290
[TBL] [Abstract][Full Text] [Related]
32. Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model.
Kramer-Marek G; Gijsen M; Kiesewetter DO; Bennett R; Roxanis I; Zielinski R; Kong A; Capala J
J Nucl Med; 2012 Apr; 53(4):629-37. PubMed ID: 22410461
[TBL] [Abstract][Full Text] [Related]
33. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
34. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.
Howe LR; Chang SH; Tolle KC; Dillon R; Young LJ; Cardiff RD; Newman RA; Yang P; Thaler HT; Muller WJ; Hudis C; Brown AM; Hla T; Subbaramaiah K; Dannenberg AJ
Cancer Res; 2005 Nov; 65(21):10113-9. PubMed ID: 16267038
[TBL] [Abstract][Full Text] [Related]
35. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.
Xu C; Langenheim JF; Chen WY
Breast Cancer Res Treat; 2012 Jul; 134(1):157-69. PubMed ID: 22270933
[TBL] [Abstract][Full Text] [Related]
36. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.
Croci S; Nanni P; Palladini A; Nicoletti G; Grosso V; Benegiamo G; Landuzzi L; Lamolinara A; Ianzano ML; Ranieri D; Dall'Ora M; Iezzi M; De Giovanni C; Lollini PL
Breast Cancer Res; 2015 May; 17(1):70. PubMed ID: 25997501
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
39. Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.
Hayashi T; Seiler R; Oo HZ; Jäger W; Moskalev I; Awrey S; Dejima T; Todenhöfer T; Li N; Fazli L; Matsubara A; Black PC
J Urol; 2015 Oct; 194(4):1120-31. PubMed ID: 26047983
[TBL] [Abstract][Full Text] [Related]
40. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers.
Morancho B; Parra-Palau JL; Ibrahim YH; Bernadó Morales C; Peg V; Bech-Serra JJ; Pandiella A; Canals F; Baselga J; Rubio I; Arribas J
Oncogene; 2013 Mar; 32(11):1452-9. PubMed ID: 22641219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
